Versican Plus Pi/L4R


canine parainfluenza virus, leptospira and rabies virus

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 17/05/2019

Authorisation details

Product details
Versican Plus Pi/L4R
Agency product number
Active substance
canine parainfluenza virus, leptospira and rabies virus.
International non-proprietary name (INN) or common name
canine parainfluenza virus, leptospira and rabies virus
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Zoetis Belgium S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Rue Laid Burniat, 1
1348 Louvain-la-Neuve

Product information

17/04/2019 Versican Plus Pi/L4R - EMEA/V/C/003682 - IB/0014

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for canidae

  • Live and inactivated viral and bacterial vaccines

Therapeutic indication

Active immunization of dogs from six weeks of age to prevent clinical signs and reduce viral excretion cause by canine parainfluenza virus, to prevent clinical signs, infection and urinary excretion cause by Leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae and to prevent mortality, clinical signs and infection cause by rabies virus.

Assessment history


How useful was this page?

Add your rating
1 rating